Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant is a research paper published in The Oncologist (2021). On theSindex it has a DataRank of 0.467. It has been cited 8 times, with 8 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.138
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 8 citers.
NCI NIH HHS
Grant: R01 CA213223
NCI NIH HHS
Grant: F30 CA216966
NIH HHS
Grant: S10 OD021616
MeSH Terms
Keywords